{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/sulfonylureas/","result":{"pageContext":{"chapter":{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas","depth":2,"htmlHeader":"<!-- begin field fd24d109-2745-4f50-adb6-e8690e11a07f --><h2>Sulfonylureas</h2><!-- end field fd24d109-2745-4f50-adb6-e8690e11a07f -->","summary":"","htmlStringContent":"<!-- begin item 66daf2f2-1bba-450b-8791-0a16c8eb88b8 --><!-- end item 66daf2f2-1bba-450b-8791-0a16c8eb88b8 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5b4eca5b-de3e-5167-8fde-13ca1c500ecf","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field f3dcdd4e-4043-42b9-be06-3f0e6353c5a5 --><h3>Recommended doses</h3><!-- end field f3dcdd4e-4043-42b9-be06-3f0e6353c5a5 -->","summary":"","htmlStringContent":"<!-- begin item 58d13491-4cba-426d-bdc9-8c7ee07195f7 --><!-- begin field c418dbd3-6dda-481a-9ba8-d25129a9295e --><p><strong>There are currently five sulfonylureas available in the UK.</strong></p><ul><li><strong>The recommended doses are:</strong><ul><li>Glibenclamide:<ul><li>5 mg daily (with, or immediately after, breakfast), dose adjusted according to response. The maximum dose is 15 mg daily. In elderly people, start treatment with 2.5 mg daily (with, or immediately after, breakfast), dose adjusted according to response.</li></ul></li><li>Gliclazide:<ul><li>Standard-release tablets: 40–80 mg daily, dose adjusted according to response; increase up to 160 mg once daily with breakfast. Doses higher than 160 mg should be divided, maximum dose 320 mg daily.</li><li>Modified-release tablets: 30 mg daily with breakfast, dose adjusted according to response every 4 weeks, or after 2 weeks if no decrease in blood glucose level. The maximum dose is 120 mg daily.</li></ul></li><li>Glimepiride:<ul><li>1 mg daily taken shortly before or with first main meal, adjusted according to response in 1 mg steps at 1–2 week intervals. The usual maximum dose is 4 mg daily (in exceptional circumstances, up to 6 mg daily may be used).</li></ul></li><li>Glipizide:<ul><li>2.5–5 mg daily taken shortly before breakfast or lunch, adjusted according to response. Doses of up to 15 mg may be given as a single dose, higher doses should be divided. The maximum dose is 20 mg daily.</li></ul></li><li>Tolbutamide:<ul><li>0.5–1.5 g daily in divided doses (with, or immediately after, meals), or as a single dose (with, or immediately after, breakfast). The maximum dose is 2 g daily.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field c418dbd3-6dda-481a-9ba8-d25129a9295e --><!-- end item 58d13491-4cba-426d-bdc9-8c7ee07195f7 -->","subChapters":[]},{"id":"d3ab356c-6b59-5488-b76e-fd82a6659f8c","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 27652ba6-58c4-4e4d-ac41-e8c04c84086a --><h3>Contraindications and cautions</h3><!-- end field 27652ba6-58c4-4e4d-ac41-e8c04c84086a -->","summary":"","htmlStringContent":"<!-- begin item 027152c8-ee30-4633-a0f3-323290461530 --><!-- begin field 9abe8c66-ab28-4bb7-a635-c070dfb27ad1 --><ul><li><strong>Do not prescribe a sulfonylurea to people with:</strong><ul><li>Acute porphyria (glibenclamide, gliclazide, and tolbutamide).</li><li>Ketoacidosis.</li><li>Severe renal impairment.<ul><li>If necessary, tolbutamide (a short-acting sulfonylurea) and gliclazide (which is principally metabolized in the liver) can be used at the lowest dose to provide blood glucose control.</li></ul></li><li>Severe hepatic impairment — increased risk of hypoglycaemia.</li></ul></li><li><strong>Prescribe a sulfonylurea with caution in people:</strong><ul><li>With mild-to-moderate renal impairment — increased risk of hypoglycaemia.</li><li>With mild-to-moderate hepatic impairment — increased risk of hypoglycaemia (with glipizide). Manufacturer advises initial dose of glipizide of 2.5 mg daily with low maintenance dose.</li><li>Who are obese — can increase weight gain.</li><li>Who are elderly — glibenclamide or glimepiride (long-acting sulfonylureas) are associated with a greater risk of prolonged hypoglycaemia in older people.</li><li>With G6PD deficiency.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 9abe8c66-ab28-4bb7-a635-c070dfb27ad1 --><!-- end item 027152c8-ee30-4633-a0f3-323290461530 -->","subChapters":[]},{"id":"22a8504b-72e5-5730-a5cf-0132a81d8ce9","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 178a5aea-9928-4b30-8812-293c98578d48 --><h3>Adverse effects</h3><!-- end field 178a5aea-9928-4b30-8812-293c98578d48 -->","summary":"","htmlStringContent":"<!-- begin item f3c26cca-e4d7-4a7f-8db6-94e270bf1a05 --><!-- begin field f7e34c76-e077-4f04-b387-a1001d7cf9c1 --><p><strong>Adverse effects of sulfonylureas </strong><strong>may include:</strong></p><ul><li>Gastrointestinal — abdominal pain, nausea, vomiting, diarrhoea, and constipation.</li><li>Hepatic impairment.</li><li>Skin — rash, pruritus, urticaria, angioedema, erythema, allergic dermatitis (usually in the first 6–8 weeks of treatment), photosensitivity reaction, Stevens-Johnson syndrome (glibenclamide).</li><li>Blood — leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia (tolbutamide).</li><li>Other:<ul><li>Hypoglycaemia.</li><li>Hyponatraemia (gliclazide, glipizide).</li><li>Dizziness, drowsiness, tremor (glipizide).</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f7e34c76-e077-4f04-b387-a1001d7cf9c1 --><!-- end item f3c26cca-e4d7-4a7f-8db6-94e270bf1a05 -->","subChapters":[]},{"id":"9589ce7a-866d-5eb8-b6f4-92878af5c687","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3b8dea77-558b-40f0-b3a0-2a7da873eb89 --><h3>What drug interactions are associated with sulfonylureas?</h3><!-- end field 3b8dea77-558b-40f0-b3a0-2a7da873eb89 -->","summary":"","htmlStringContent":"<!-- begin item 02d2869f-d8e3-44f7-9a7c-20f3df2513ac --><!-- begin field a492301a-2e0c-4b09-8a32-cb9ea5a436fa --><ul><li><strong>Possible drug interactions associated with sulfonylureas include:</strong><ul><li>Beta-blockers — the warning signs of hypoglycaemia (such as tremor) may be masked when a sulfonylurea is given with a beta-blocker.</li><li>Colesevelam — the absorption of glibenclamide, glimepiride, and glipizide may be reduced by colesevelam.<ul><li>The manufacturer of glimepiride advises that it is taken at least 4 hours before colesevelam. </li><li>Other drugs should be taken at least 4 hours before or after colesevelam, to reduce possible interference with absorption.</li></ul></li><li>Fibrates — there may be improved glucose tolerance and an additive effect when a sulfonylurea is given with a fibrate.</li><li>Fluconazole — the plasma concentration of sulfonylureas may be increased by fluconazole.</li><li>Fluvastatin — the plasma concentration of glibenclamide may be increased by fluvastatin.</li><li>Norfloxacin — the effects of glibenclamide may be enhanced by norfloxacin.</li><li>Phenytoin and fosphenytoin — tolbutamide transiently increases plasma concentration of these drugs (possibility of toxicity).</li><li>Rifamycins — the metabolism of sulfonylureas may be accelerated by rifamycins (reduced effect).</li><li>Ritonavir — the plasma concentration of tolbutamide may be increased by ritonavir.</li><li>St John’s wort — can cause poor blood glucose control when taken in combination with gliclazide.</li><li>Topiramate — the plasma concentration of glibenclamide may be reduced by topiramate.</li><li>Trimethoprim — the effects of sulfonylureas may be enhanced by trimethoprim.</li><li>Voriconazole and ketoconazole — the plasma concentration of sulfonylureas may be increased by voriconazole, and plasma concentration of tolbutamide may be increased by ketoconazole.</li><li>Other antidiabetic drugs — the dose of the sulfonylurea (and in some cases the concomitant antidiabetic drug) may need to be reduced, to reduce the risk of hypoglycaemia.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>The blood glucose-lowering effects of sulfonylureas may be enhanced by: </strong><ul><li>Alcohol.</li><li>Anabolic steroids.</li><li>Angiotensin-converting enzyme (ACE) inhibitors.</li><li>Chloramphenicol.</li><li>Cimetidine.</li><li>Coumarins.</li><li>Disopyramide (enhances hypoglycaemic effect of gliclazide).</li><li>Leflunomide (enhances hypoglycaemic effect of tolbutamide).</li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Miconazole (avoid concurrent use with gliclazide and glipizide).</li><li>Nonsteroidal anti-inflammatory drugs.</li><li>Testosterone. </li><li>Tetracyclines.</li><li>Trimethoprim (rare).</li></ul></li><li><strong>The blood glucose-lowering effects of sulfonylureas may be antagonized by: </strong><ul><li>Corticosteroids. </li><li>Diuretics (thiazide and related, and loop). </li><li>Oestrogens and progestogens.</li><li>Phenothiazines.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field a492301a-2e0c-4b09-8a32-cb9ea5a436fa --><!-- end item 02d2869f-d8e3-44f7-9a7c-20f3df2513ac -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}